On November 5, 2020, Regeneron Pharmaceuticals published a redacted version of the contract awarding the company $450 million taxpayers’ dollars for the large-scale manufacture of Regeneron’s investigational COVID-19 antibody treatment. The contract uses Other Transactions Authority to weaken the U.S.… Continue Reading
A contract between Regeneron and Advanced Technology International (ATI) involving $450 million in taxpayer funding uses the “Other Transactions Authority” or OTA, to avoid Bayh-Dole safeguards on patent rights. ATI is entering into purchase agreements on behalf of the Department… Continue Reading
Lilly recently requested an emergency use authorization for LY-CoV555, an antibody treatment candidate against COVID-19. Like other COVID-19 candidates, the discovery of LY-CoV555 was heavily supported by the U.S. government. The government of Canada has also awarded millions to manufacture… Continue Reading
Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge U.S. government funding in patents is required under an existing contract between Regeneron and the Biomedical Advanced Research and Development… Continue Reading
KEI Research Note 2020:4 Regeneron failed to disclose BARDA funding in their REGN-COV2 patent Luis Gil Abinader October 20, 2020 Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge… Continue Reading
On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading
On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading
On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading
United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading
Through a Freedom of Information Act (FOIA) request, Knowledge Ecology International (KEI) has obtained copies of two vaccine-related contracts entered into by the Biomedical Advanced Research and Development Authority (BARDA), one with AstraZeneca related to COVID-19 vaccines and one with… Continue Reading